Our top pick for
Abeona Therapeutics Inc is a biotechnology business based in the US. Abeona Therapeutics shares (ABEO) are listed on the NASDAQ and all prices are listed in US Dollars. Abeona Therapeutics employs 88 staff and has a trailing 12-month revenue of around USD$7 million.
|52-week range||USD$0.9895 - USD$3.79|
|50-day moving average||USD$2.3636|
|200-day moving average||USD$1.7949|
|Wall St. target price||USD$5.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.586|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$7 million|
|Gross profit TTM||USD$-48,566,000|
|Return on assets TTM||-20.87%|
|Return on equity TTM||-80.35%|
|Market capitalisation||USD$226.9 million|
TTM: trailing 12 months
There are currently 3.0 million Abeona Therapeutics shares held short by investors – that's known as Abeona Therapeutics's "short interest". This figure is 2.6% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting Abeona Therapeutics shares can be evaluated.
Abeona Therapeutics's "short interest ratio" (SIR) is the quantity of Abeona Therapeutics shares currently shorted divided by the average quantity of Abeona Therapeutics shares traded daily (recently around 5.4 million). Abeona Therapeutics's SIR currently stands at 0.55. In other words for every 100,000 Abeona Therapeutics shares traded daily on the market, roughly 550 shares are currently held short.
However Abeona Therapeutics's short interest can also be evaluated against the total number of Abeona Therapeutics shares, or, against the total number of tradable Abeona Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abeona Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Abeona Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0361% of the tradable shares (for every 100,000 tradable Abeona Therapeutics shares, roughly 36 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abeona Therapeutics.
Find out more about how you can short Abeona Therapeutics stock.
We're not expecting Abeona Therapeutics to pay a dividend over the next 12 months.
Abeona Therapeutics's shares were split on a 1:50 basis on 24 October 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Abeona Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Abeona Therapeutics shares which in turn could have impacted Abeona Therapeutics's share price.
Over the last 12 months, Abeona Therapeutics's shares have ranged in value from as little as $0.9895 up to $3.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abeona Therapeutics's is 1.5293. This would suggest that Abeona Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.